How to Enter Japan’s Elderly Care Market: A Step-by-Step Guide for International Companies

05 Jun How to Enter Japan’s Elderly Care Market: A Step-by-Step Guide for International Companies

Japan’s elderly care market is not just another international expansion opportunity — it is the proving ground for aging-society technology worldwide. For any foreign company serious about selling elderly care technology in Japan, understanding the regulatory terrain, cultural expectations, and partnership dynamics is the difference between a costly failure and a scalable foothold across Asia. This japan elderly care market entry guide walks you through every stage, from first feasibility assessment to post-entry scaling, with the concrete numbers and regulatory details that senior decision-makers need to greenlight investment.

Why Japan Should Be Your First Market for Aging Technology

Japan has the largest elderly population proportion globally at 29.4%, with residents aged 65 and older totaling 36.19 million. This demographic reality has created an elderly care services market valued at $11.17 billion in 2023, growing at a CAGR of 7.07% — and specialized segments are expanding far faster. Japan’s elder care assistive robots market alone is projected to reach $871.3 million by 2033, growing at 15.3% annually.

This growth is not left to the private sector alone. The Japanese government has committed approximately $300 million in targeted funding for care robotics research and allocated 13.2 trillion yen in care benefits for the 2026 fiscal year. Broader national strategies like Society 5.0 and Moonshot R&D programs explicitly position aging as a technological opportunity, creating demonstration zones and funding streams that foreign entrants can tap into.

For international companies evaluating the japan aging market opportunity, Japan offers a strategic advantage beyond its domestic market: credibility transfer. As Carnegie Endowment research on Japan’s aging society as a technological opportunity documents, success in Japan’s demanding regulatory and cultural environment creates immediate credibility across South Korea, Taiwan, and Southeast Asia. According to JETRO assessments, roughly 65% of foreign companies view Japan as a critical test market for aging solutions — even as they acknowledge significant entry barriers. Those barriers are real, but they are navigable with the right strategy.

Understanding the Regulatory Landscape: PMDA and the PMD Act

Any foreign company entering Japan’s elderly care market must first understand the Pharmaceutical and Medical Device Act (PMD Act), which governs most clinically oriented care technologies through the Pharmaceuticals and Medical Devices Agency (PMDA). Under this framework, devices are classified into four risk-based tiers that determine the approval pathway, timeline, and cost.

Sources: Credevo Japan device approval analysis, MasterControl PMDA overview, Asia Actual registration guide

Most care robots, fall-detection sensors, and AI monitoring systems land in Class II or III. Software classified as a medical device (SaMD) — such as AI-based fall-risk scoring or remote cognitive assessment tools — follows the same framework, with PMDA issuing specific guidelines for AI-based medical devices and generative AI safety evaluation.

Foreign manufacturers cannot submit directly. They must work through a Marketing Authorization Holder (MAH) based in Japan, who assumes legal responsibility for regulatory compliance, quality management, and post-market surveillance. Additionally, all foreign production sites must complete Foreign Manufacturer Registration with MHLW and implement a quality management system conforming to Japan’s QMS Ordinance, which is largely harmonized with ISO 13485 but includes Japan-specific provisions. Total submission costs range from $20,000 to $120,000 depending on device class, with the Digital Therapeutics Alliance reporting fees around 13 million yen (~$113,900) for certain SaMD product reviews and inspections.

Five Common Market Entry Barriers and How to Overcome Them

1. Regulatory Complexity

The four-tier PMDA system, combined with QMS audits, Foreign Manufacturer Registration, and MAH requirements, creates a regulatory process that feels impenetrable without guidance. The solution: engage PMDA’s pre-submission consultation service early. PMDA actively encourages developers to clarify classification, evidence requirements, and study design before committing resources. This single step prevents the most common cause of delays — misclassification and incomplete dossiers.

2. Cultural Adaptation Gaps

JETRO assessments indicate that over 65% of foreign entrants fail to achieve meaningful market adoption within 24 months, primarily due to inadequate cultural adaptation. Japanese elderly care emphasizes collective decision-making involving family, community stakeholders, and care staff — a fundamentally different model from Western individualistic approaches. Products designed without understanding these dynamics routinely fail, regardless of technical merit. Localization means far more than translation; it requires redesigning user experiences, consent workflows, and support models for the Japanese care context.

3. Language Barriers at Every Stage

The language challenge extends beyond product interfaces. Municipal tender documents are written in specialized bureaucratic Japanese. Care facility staff communicate in domain-specific terminology. Patient and family engagement requires culturally appropriate communication styles. Companies that rely on ad-hoc translation services miss critical nuances in regulatory submissions, partnership negotiations, and end-user training — each of which can derail an otherwise sound market entry strategy.

4. Fragmented Market Administration

Japan’s Long-Term Care Insurance system operates through 1,741 municipal-level administration bodies, each implementing slightly different service protocols and eligibility criteria. A product that gains traction in Tokyo may face entirely different procurement processes, subsidy structures, and facility requirements in Osaka or Fukuoka. Successful entrants build relationships municipality by municipality, often starting with pilot deployments in two or three strategic regions before attempting national distribution.

5. Reimbursement Navigation

The Long-Term Care Insurance system is the primary funding mechanism for elderly care services, with total care costs reaching 11.9 trillion yen in 2024. For a foreign company selling elderly care technology in Japan, reimbursement eligibility often determines whether a product is commercially viable. Technologies that qualify for care insurance coverage or government subsidy programs gain a massive adoption advantage, but navigating these pathways requires deep understanding of reimbursement categories, evidence requirements, and the annual budget cycle.

Finding and Evaluating a Local Partner

Why a Bilingual MAH with Domain Expertise Is Non-Negotiable

Regulatory structure makes a Japanese MAH mandatory, but the right MAH does far more than file paperwork. A partner with genuine bilingual capability and elderly care domain expertise can navigate PMDA consultations, interpret regulatory feedback in strategic context, manage facility relationships during pilots, and communicate effectively with municipal procurement offices. Translation-only firms cannot fill this role — they lack the regulatory judgment and industry relationships that determine whether submissions succeed or stall.

Evaluating Partners Across Three Dimensions

Assess potential partners across regulatory capability (track record of PMDA submissions in your device class), cultural competence (experience bridging foreign and Japanese organizational cultures), and technical understanding (ability to evaluate your technology’s clinical and operational fit within Japanese care workflows). Request specific case studies of previous market entry engagements, including timelines achieved and obstacles encountered.

Red Flags in Partner Selection

Be wary of firms that position themselves as full-service partners but lack direct PMDA submission experience, rely entirely on subcontracted translation, or cannot demonstrate existing relationships with care facility operators. Strategic consultancies that combine regulatory navigation with market development — such as DMPJ’s bilingual elderly care market entry support — offer integrated capability that pure regulatory agencies or pure translation firms cannot match.

Building Facility Relationships for Pilots

Pilot deployments in Japanese care facilities are essential for generating the localized performance data that PMDA increasingly expects and that facility operators demand before committing to procurement. Start with two or three facilities willing to participate in structured evaluations. Research from a study of Japanese nursing homes found that robot adoption was positively associated with increased caregiver retention and reduced use of patient restraints — the kind of measurable outcomes that build the business case for broader adoption.

Timeline, Budget, and Milestones for Japan Market Entry

The 18–24 Month Reality

From initial planning to first revenue, most foreign companies should expect an 18–24 month timeline for Japan market entry in the elderly care sector. Companies that underestimate this timeline and rush submissions typically face costly delays from PMDA deficiency queries or failed pilot deployments.

Budget Framework

Key Milestones

The critical path typically follows this sequence: QMS certification of your manufacturing site, initial PMDA pre-submission consultation to confirm classification and evidence strategy, preparation and submission of regulatory dossier, pilot deployment in Japanese facilities during the review period, and subsidy application to align with government funding cycles. Each milestone has dependencies — QMS certification must precede or parallel dossier submission, and pilot data often strengthens the regulatory case.

Expedited Pathways

Two programs can compress timelines for qualifying products. The Sakigake Designation System targets globally pioneering innovations with a six-month target review time, dedicated PMDA liaison support, and prioritized consultations. Products must demonstrate novel treatment or diagnostic capability, target a severe condition, and show exceptionally high efficacy potential. The Conditional Early Approval (Fast-Break) scheme allows market access based on preliminary evidence when conducting large confirmatory trials is impractical, in exchange for rigorous post-marketing surveillance commitments. Both pathways reward companies that engage PMDA early and build compelling preliminary evidence packages.

Beyond Entry: Scaling in Japan and Across Asia

Leveraging Japan Approval for Regional Credibility

Japan’s regulatory approval carries weight throughout Asia-Pacific. South Korea’s MFDS, Taiwan’s TFDA, and ASEAN regulatory bodies recognize Japan’s rigorous evaluation standards, and a PMDA-approved product enters regional conversations with built-in credibility. Companies that treat Japan as an isolated market miss the multiplier effect: a successful Japanese deployment, complete with localized clinical data and facility testimonials, dramatically accelerates market entry in neighboring aging societies.

Building Reimbursement Evidence

Sustainable revenue in Japan depends on reimbursement eligibility under the Long-Term Care Insurance system or inclusion in government subsidy programs. This requires generating Japanese-specific outcome data that demonstrates measurable improvements in care efficiency, resident safety, or staff productivity. Facilities that participated in your pilot program become the evidence base for reimbursement applications — another reason to invest heavily in structured pilot design from the outset.

Participating in National Innovation Programs

Japan’s Society 5.0 demonstration zones and Moonshot R&D programs offer foreign companies opportunities to participate in government-backed innovation ecosystems. These programs provide access to funding, facility partnerships, and regulatory learning opportunities that accelerate market understanding. Through Daisho Media Partners’ Japan market entry consulting for aging solutions, international companies can identify and access the specific programs most relevant to their technology category and strategic goals.

Entering Japan’s elderly care market demands more than a good product — it requires bilingual regulatory expertise, deep cultural understanding, and established relationships across the care ecosystem. DMPJ specializes in guiding international companies through every stage of Japan market entry, from PMDA strategy to facility-level deployment. Visit DMPJ’s Elderly Care Innovation service page to learn how our bilingual team can turn Japan’s aging crisis into your growth opportunity.